Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors
暂无分享,去创建一个
V. Mazzaferro | F. D. De Braud | C. Brambilla | P. Maisonneuve | A. Faggiano | M. Milione | L. Giacomelli | M. Rubino | A. Pellegrinelli | S. Pusceddu | R. Buzzoni | J. Coppa | G. Centonze | L. Concas | Francesca Dominoni
[1] D. Neuberg,et al. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. , 2016, JAMA oncology.
[2] U. Pastorino,et al. Conversion to stem‐cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells , 2015, Molecular oncology.
[3] F. Grillo,et al. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? , 2016, Endocrine.
[4] R. Fiocca,et al. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor , 2015, Neuroendocrinology.
[5] W. Dinjens,et al. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. , 2015, The Journal of clinical endocrinology and metabolism.
[6] A. Gill,et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. , 2015, Human pathology.
[7] P. Ferrari,et al. Cellular Plasticity, Cancer Stem Cells and Metastasis , 2015 .
[8] H. Falhammar,et al. Ileal neuroendocrine tumors and heart: not only valvular consequences , 2015, Endocrine.
[9] C. Stratakis,et al. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations , 2014, Endocrine.
[10] W. ElShamy,et al. Overview: cellular plasticity, cancer stem cells and metastasis. , 2013, Cancer letters.
[11] V. Mazzaferro,et al. Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum , 2012, Cancers.
[12] I. Tomlinson,et al. SDH mutations in cancer. , 2011, Biochimica et biophysica acta.
[13] B. Niederle,et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.
[14] A. Chou,et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. , 2010, Human pathology.
[15] A. Chou,et al. Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.
[16] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Kos-Kudła,et al. Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin , 2007, Neuroendocrinology.
[18] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[19] F. Keleştimur,et al. Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.
[20] N. Lemoine,et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. , 2006, Endocrine-related cancer.
[21] I. Modlin,et al. Therapeutic options for gastrointestinal carcinoids. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.